找回密码
 立即注册

微信扫码登录

搜索

[不可手术无驱动] 不可切除局部晚期非小细胞肺癌无驱动基因:放化疗加维持免疫治疗【汇总】

[复制链接]
阳光肺科 发表于 2026-1-11 00:37:09 | 显示全部楼层 |阅读模式
研究PACIFICGEMSTONE-301PACIFIC-5
发表年度202220222025
mPFS,月16.9月 vs 5.6月,HR=0.559.0月 vs  5.6月14.0月 vs  6.5月,HR=0.75,P=0.038
5年PFS,%33.1% vs 19.0%
mOS,月47.5月 vs 29.1月,HR=0.7238.3月 vs 32.5月
5年OS,%42.9% vs 33.4%
← 横向拖动查看完整表格 →


PACIFIC
  • 2022年
  • mPFS 16.9月 vs 5.6月
  • mOS 47.5月 vs 29.1月

GEMSTONE-301
  • 2022年
  • mPFS 9.0月 vs  5.6月

PACIFIC-5
  • 2025年
  • mPFS 14.0月 vs  6.5月
  • mOS  38.3月 vs 32.5月


参考文献
[1]Antonia SJ, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2021;39(15):1647-1657.
[2]Wu YL, Wu L, Bi N, et al. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. Journal of Hematology & Oncology. 2025;18(1):111.
[3]Zhang Z, Bi N, Wang Y, et al. The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist). J Clin Oncol. 2025;43(16_suppl):8012.
[4]Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024;391(7):585-597.
[5]Meng X, et al. Aumolertinib as consolidation therapy for unresectable stage III EGFR-mutated NSCLC: The phase III POLESTAR trial. Presented at 2024 WCLC, Abstract PL04.13. J Thorac Oncol. 2024.
[6]Bi N, Wang JY, Jiang W, et al. Survival of induction aumolertinib followed by aumolertinib and concurrent radiotherapy (RT) in unresectable EGFR-mutated stage III NSCLC: Final analysis of the phase III ADVANCE trial and real-world data. J Clin Oncol. 2025;43(16_suppl):8048.
[7]Tan F, Jiang Y, Duan J, et al. Long-term outcomes and clinical features of stage III non-small-cell lung cancer harboring ALK rearrangements: a multicenter retrospective study of 176 patients. J Natl Cancer Cent. 2026;6(2):159-165.

给我们建议|手机版|阳光肺科 ( 粤ICP备2020077405号-1 )

GMT+8, 2026-11-13 03:17

Powered by Discuz! X3.5

© 2001-2026 Discuz! Team.

快速回复 返回顶部 返回列表